Lilly buys AtaiBeckley·$3.8bn Otsuka buys Transcend·$1.2bn AbbVie buys Gilgamesh·$1.2bn atai buys Beckley Psytech·terms undisclosed AbbVie takes an option on Gilgamesh·$2bn Lilly buys AtaiBeckley·$3.8bn Otsuka buys Transcend·$1.2bn AbbVie buys Gilgamesh·$1.2bn atai buys Beckley Psytech·terms undisclosed AbbVie takes an option on Gilgamesh·$2bn Lilly buys AtaiBeckley·$3.8bn Otsuka buys Transcend·$1.2bn AbbVie buys Gilgamesh·$1.2bn atai buys Beckley Psytech·terms undisclosed AbbVie takes an option on Gilgamesh·$2bn

Next issueIssue 16 · Tue 29 Sep

atai Therapeutics

Every issue covering atai Therapeutics.

1 issue

2026-09-01No. 12
Lilly’s depression trial went from one approval to four in seven days.